It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: SpartanStoic
“ Wear your mask.”
“No. Fight me.”
originally posted by: EndtheMadnessNow
originally posted by: all2human
i'm wondering if cancelling the super bowl would be the prudent thing to do
LOL. Sacrifice billions in revenue. Never.
Apple is closing ALL stores, corporate offices, and contact centers in China due to Coronavirus through Feb. 9, company says in statement.
Biotech company Moderna is testing a vaccine that uses a patient's own messenger RNA — a nucleic acid that translates genetic code into proteins. The vaccine concept has already been proven in the flu and another infection called cytomegalovirus, or CMV, Carr said.
Further, privately held competitor CureVac has announced its plan to develop a vaccine against this form of the coronavirus, Carr said. Similarly, Inovio Pharmaceuticals (INO) received a grant from the Coalition for Epidemic Preparedness Innovations to test a DNA-based vaccine.
Vaccine programs are also underway at Johnson & Johnson (JNJ), Novavax (NVAX) and Vaxart (VXRT), he said. Vaccine technology has advanced markedly over the years. But Carr doubts these efforts will make much of an impact on the coronavirus.
Johnson & Johnson on Wednesday unveiled its “multi-pronged” response that includes a vaccine R&D effort in a "skunkworks" in the Netherlands, according to Chief Scientific Officer Paul Stoffels. It's also testing whether existing medicines could tackle the novel virus and donating antiviral drugs to Chinese hospitals.
J&J and others used similar platforms to create an Ebola vaccine and deliver two million doses to West Africa in less than six months. The company also has used the platforms to create vaccines for HIV and Zika.
The company is conducting its Wuhan coronavirus research in Leiden, in the Netherlands. Stoffels spoke to The Inquirer from Leiden after addressing scientists at its labs.